A pilot study of combination intraperitoneal recombinant human endostatin and chemotherapy for refractory malignant ascites secondary to ovarian cancer

Palliative Chemotherapy for Malignant Ascites Secondary to Ovarian Cancer

(2012) Yuliya Malayev et al.   American Journal of Hospice & Palliative Medicine

Malignant ascites: pathophysiology and treatment

(2012) Emanuel Cavazzoni et al.   International Journal of Clinical Oncology

The inhibitory effects of Endostar combined with chemotherapy on human esophageal squamous cell carcinoma xenograft in mice

(2012) Liang Chang et al.   MOLECULAR BIOLOGY REPORTS

Systematic review and meta-analysis of Endostar (rh-endostatin) combined with chemotherapy versus chemotherapy alone for treating advanced non-small cell lung cancer

(2012) Rong Biaoxue et al.   World Journal of Surgical Oncology

Global cancer statistics

(2011) Ahmedin Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Endostar, a modified recombinant human endostatin, exhibits synergistic effects with dexamethasone on angiogenesis and hepatoma growth

(2011) Xing-Qi Li et al.   CANCER LETTERS

Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study

(2011) Walter H Gotlieb et al.   LANCET ONCOLOGY

Dexamethasone reduces tumor recurrence and metastasis after pancreatic tumor resection in SCID mice

(2010) Jan-Hendrik Egberts et al.   CANCER BIOLOGY & THERAPY

A novel perspective for an orphan problem: Old and new drugs for the medical management of malignant ascites

(2010) S. Barni et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial

(2010) Markus M. Heiss et al.   INTERNATIONAL JOURNAL OF CANCER

Patient-reported outcomes in support of oncology product labeling claims: regulatory context and challenges

(2010) Yanni Hao   Expert Review of Pharmacoeconomics & Outcomes Research

Intraperitoneal VEGF Inhibition Using Bevacizumab: A Potential Approach for the Symptomatic Treatment of Malignant Ascites?

(2009) S. Kobold et al.   ONCOLOGIST

Endostar Suppresses Invasion Through Downregulating the Expression of Matrix Metalloproteinase-2/9 in MDA-MB-435 Human Breast Cancer Cells

(2008) Na Lu et al.   EXPERIMENTAL BIOLOGY AND MEDICINE

Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer

(2008) Chad A. Hamilton et al.   GYNECOLOGIC ONCOLOGY